LOQTORZI® (toripalimab-tpzi)
1L Nasopharyngeal Carcinoma (combo with chemotherapy)
Key Facts
About Coherus Oncology
Coherus Oncology is dedicated to extending patient survival through a portfolio of innovative immuno-oncology (I-O) combination therapies. The company has successfully commercialized LOQTORZI® and is advancing multiple clinical-stage candidates, including tagmokitug (anti-CCR8) and casdozokitug (IL-27 antagonist), across various solid tumors. With a leadership team of seasoned industry veterans and a strategic focus on novel I-O mechanisms, Coherus aims to transform cancer treatment by addressing key resistance pathways in the tumor microenvironment.
View full company profileAbout Coherus Oncology
Coherus Oncology is dedicated to extending patient survival through a portfolio of innovative immuno-oncology (I-O) combination therapies. The company has successfully commercialized LOQTORZI® and is advancing multiple clinical-stage candidates, including tagmokitug (anti-CCR8) and casdozokitug (IL-27 antagonist), across various solid tumors. With a leadership team of seasoned industry veterans and a strategic focus on novel I-O mechanisms, Coherus aims to transform cancer treatment by addressing key resistance pathways in the tumor microenvironment.
View full company profileAbout Coherus BioSciences
Coherus BioSciences has successfully pivoted from a pure-play biosimilar company to an integrated oncology firm with a dual revenue and R&D strategy. Its commercial biosimilars (UDENYCA®, YUSIMRY™) provide a cash-generative foundation, while its innovative immuno-oncology pipeline, anchored by the approved anti-PD-1 therapy LOQTORZI® (toripalimab) and novel candidates like tagmokitug (anti-CCR8) and casdozokitug (anti-IL-27), targets significant market opportunities in oncology. The company's strategy is to leverage its commercial infrastructure and regulatory expertise to efficiently advance combination therapies that overcome immune resistance.
View full company profileAbout Coherus BioSciences
Coherus BioSciences has successfully pivoted from a pure-play biosimilar company to an integrated oncology firm with a dual revenue and R&D strategy. Its commercial biosimilars (UDENYCA®, YUSIMRY™) provide a cash-generative foundation, while its innovative immuno-oncology pipeline, anchored by the approved anti-PD-1 therapy LOQTORZI® (toripalimab) and novel candidates like tagmokitug (anti-CCR8) and casdozokitug (anti-IL-27), targets significant market opportunities in oncology. The company's strategy is to leverage its commercial infrastructure and regulatory expertise to efficiently advance combination therapies that overcome immune resistance.
View full company profile